Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too?
The Lilly Foundation is unloading 300,000 shares of the stock.
Eli Lilly's biggest shareholder, the Lilly Foundation, is selling 300,000 shares of the pharmaceutical company, valued at $347 million. Despite this significant sale, other shareholders should not consider selling their own stock. The foundation is obligated to make this required annual charity payment, and the decision is not due to a change in sentiment towards Lilly's stock.
Instead, Lilly is currently leading in the development of GLP-1 drugs, with its Mounjaro and Zepbound gaining massive popularity. Morgan Stanley projects that the GLP-1 market will more than double by 2035. Analysts also expect Lilly's share price to reach $1,328, 10% higher than the current price. So, the recommendation is for investors to buy Lilly stock, not sell it.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
